Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jul 14;36(27):1762-71.
doi: 10.1093/eurheartj/ehv104. Epub 2015 Apr 20.

Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention

Dániel Aradi  1 , Ajay Kirtane  2 , Laurent Bonello  3 , Paul A Gurbel  4 , Udaya S Tantry  4 , Kurt Huber  5 , Matthias K Freynhofer  5 , Jurrien ten Berg  6 , Paul Janssen  6 , Dominick J Angiolillo  7 , Jolanta M Siller-Matula  8 , Rossella Marcucci  9 , Giuseppe Patti  10 , Fabio Mangiacapra  10 , Marco Valgimigli  11 , Olivier Morel  12 , Tullio Palmerini  13 , Matthew J Price  14 , Thomas Cuisset  15 , Adnan Kastrati  16 , Gregg W Stone  2 , Dirk Sibbing  17
Affiliations
Review

Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention

Dániel Aradi et al. Eur Heart J. .

Abstract

Aims: Although platelet reactivity during P2Y12-inhibitors is associated with stent thrombosis (ST) and bleeding, standardized and clinically validated thresholds for accurate risk stratification after percutaneous coronary intervention (PCI) are lacking. We sought to determine the prognostic value of low platelet reactivity (LPR), optimal platelet reactivity (OPR), or high platelet reactivity (HPR) by applying uniform cut-off values for standardized devices.

Methods and results: Authors of studies published before January 2015, reporting associations between platelet reactivity, ST, and major bleeding were contacted for a collaborative analysis using consensus-defined, uniform cut-offs for standardized platelet function assays. Based on best available evidence for each device (exploratory studies), LPR-OPR-HPR categories were defined as <95, 95-208, and >208 PRU for VerifyNow, <19, 19-46, and >46 U for the Multiplate analyser and <16, 16-50, and >50% for VASP assay. Seventeen studies including 20 839 patients were used for the analysis; 97% were treated with clopidogrel and 3% with prasugrel. Patients with HPR had significantly higher risk for ST [risk ratio (RR) and 95% CI: 2.73 (2.03-3.69), P < 0.00001], yet a slight reduction in bleeding [RR: 0.84 (0.71-0.99), P = 0.04] compared with those with OPR. In contrast, patients with LPR had a higher risk for bleeding [RR: 1.74 (1.47-2.06), P < 0.00001], without any further benefit in ST [RR: 1.06 (0.68-1.65), P = 0.78] in contrast to OPR. Mortality was significantly higher in patients with HPR compared with other categories (P < 0.05). Validation cohorts (n = 14) confirmed all results of exploratory studies (n = 3).

Conclusions: Platelet reactivity assessment during thienopyridine-type P2Y12-inhibitors identifies PCI-treated patients at higher risk for mortality and ST (HPR) or at an elevated risk for bleeding (LPR).

Keywords: P2Y12-inhibitors; Platelet reactivity; Stent thrombosis, Bleeding.

PubMed Disclaimer

Comment in

Publication types

MeSH terms